2. Signaling Pathways
  3. Anti-infection
  4. HCV
  5. HCV Inhibitor

HCV Inhibitor

HCV Inhibitors (285):

Cat. No. Product Name Effect Purity
  • HY-12429A
    Beclabuvir hydrochloride
    		Inhibitor
    Beclabuvir (BMS-791325) hydrochloride is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, and inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 with IC50 of < 28 nM.
  • HY-173011
    RJS308
    		Inhibitor
    RJS308 is the PROTAC degrader for cyclosporin A (CypA) with a DC50 of 284 nM. RJS308 exhibits antiviral activcity through inhibition of HIV-1 and HCV replication. (Pink: ligand for target protein CypA ligand-2 (HY-173012); Black: linker (HY-W123015); Blue: ligand for E3 ligase VHL (S,R,S)-AHPC-Me (HY-112078))
  • HY-12530R
    Velpatasvir (Standard)
    		Inhibitor
    Velpatasvir (Standard) is the analytical standard of Velpatasvir. This product is intended for research and analytical applications. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 2.16 μM.
  • HY-B0434R
    Ribavirin (Standard)
    		Inhibitor
    Ribavirin (Standard) is the analytical standard of Ribavirin. This product is intended for research and analytical applications. Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV. Ribavirin also has anti-orthopoxvirus and anti-variola activities.
  • HY-N0494R
    Gentiopicroside (Standard)
    		Inhibitor
    Gentiopicroside (Standard) is the analytical standard of Gentiopicroside. This product is intended for research and analytical applications. Gentiopicroside, a naturally occurring iridoid glycoside, inhibits P450 activity, with an IC50 and a Ki of 61 μM and 22.8 μM for CYP2A6; Gentiopicroside has anti-inflammatoryand antioxidative effects.
  • HY-10466S1
    Daclatasvir-13C2,d6
    		Inhibitor
    Daclatasvir-13C2,d6 (BMS-790052-13C2,d6) is 13C and deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 μM and 3.27 μM, respectively.
  • HY-50695
    GSK 625433
    		Inhibitor
    GSK 625433 is a hepatitis C virus inhibitor.
  • HY-W103964
    HCV-IN-47
    		Inhibitor
    HCV-IN-47 (Compound (R)-1) shows anti-hepatitis C virus (HCV) activity with an EC50 value of 0.032 μM. HCV-IN-47 is promising for research of hepatitis C virus pathogenesis, and host-virus interaction.
  • HY-173009
    PROTAC CG167
    		Inhibitor
    PROTAC CG167 is a selective and potent CypA PROTAC degrader. PROTAC CG167 degrades CypA in a dose-dependent manner (Jurkat: DC50: 123 nM). PROTAC CG167 can inhibit HIV-1 and HCV and exhibits antiviral activity. (Pink: CypA Ligand (HY-170997); Black: Linker (HY-W123015); Blue: E3 Ligase Ligand (HY-112078))
  • HY-15602D
    Ledipasvir (diacetone)
    		Inhibitor
    Ledipasvir diacetone (GS-5885 diacetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC50 values of 34 pM against GT1a and 4 pM against GT1b replicon.
  • HY-12530S1
    Velpatasvir-d3
    		Inhibitor
    Velpatasvir-d3 (GS-5816-d3) is deuterium labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 2.16 μM.
  • HY-W128400
    3′-Deoxy-3′-fluoroguanosine
    		Inhibitor
    3′-Deoxy-3′-fluoroguanosine exhibits antiviral activity against tick-borne encephalitis virus (TBEV), through interaction with NS5B RdRp of HCV, resulting in suppression of viral RNA synthesis by disruption of further extension of the replicating viral RNA.
  • HY-15005R
    Sofosbuvir (Standard)
    		Inhibitor
    Sofosbuvir (Standard) is the analytical standard of Sofosbuvir. This product is intended for research and analytical applications. Sofosbuvir (GS-7977) is an HCV RNA replication inhibitor with an EC50 of 92 nM.
  • HY-15789R
    Elbasvir (Standard)
    		Inhibitor
    Elbasvir (Standard) is the analytical standard of Elbasvir. This product is intended for research and analytical applications. Elbasvir (MK-8742) is a hepatitis C virus nonstructural protein 5A (HCV NS5A) inhibitor with EC50s of 4, 3 and 3 nM against genotype 1a, 1b, and 2a, respectively.
  • HY-173013
    TWH106
    		Inhibitor
    TWH106 is an inhibitor for Cyclophilin (Cyp) that exhibits good affinity to CypA and CypB with KD of 53 nM and 139 nM. TWH106 inhibits the replication of HIV and HCV, exhibiting antiviral activity.
  • HY-N6936R
    Sennidin A (Standard)
    		Inhibitor
    Sennidin A (Standard) is the analytical standard of Sennidin A. This product is intended for research and analytical applications. Sennidin A, isolated from the leaves of Cassia angustifolia, inhibits HCV NS3 helicase, with an IC50 of 0.8 μM. Sennidin A induces phosphorylation of Akt and glucose transporter 4 (GLUT4) translocation. Sennidin A stimulates the glucose incorporation.
  • HY-10237R
    Boceprevir (Standard)
    		Inhibitor
    Boceprevir (Standard) is the analytical standard of Boceprevir. This product is intended for research and analytical applications. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay. Boceprevir inhibits SARS-CoV-2 3CLpro activity.
  • HY-120233
    MK-8876
    		Inhibitor
    MK-8876 is an inhibitor of HCV NS5b site D, which can be used in the research of hepatitis C virus .
  • HY-10300R
    Narlaprevir (Standard)
    		Inhibitor
    Narlaprevir (Standard) is the analytical standard of Narlaprevir. This product is intended for research and analytical applications. Narlaprevir (SCH 900518) is a selective and orally bioavailable NS3 protease inhibitor with a Ki value of 6 nM and an EC90 value of 40 nM[1]. Narlaprevir also inhibits the HCV nonstructural protein 3 serine protease[2]. Narlaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 2.3 μM[3].
  • HY-W749691
    (S)-Velpatasvir-13C,d3
    		Inhibitor
    (S)-Velpatasvir-13C,d3 ((S)-GS-5816-13C,d3) is 13C labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 2.16 μM.